about
De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockDe-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockCarbapenems: past, present, and futureCrystal Structures of Biapenem and Tebipenem Complexed with Penicillin-Binding Proteins 2X and 1A from Streptococcus pneumoniaeTreatment of anaerobic infectionThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemClinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyEvolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?Antibiotics in the clinical pipeline at the end of 2015.Celecoxib Enhances the Efficacy of Low-Dose Antibiotic Treatment against Polymicrobial Sepsis in Mice and Clinical Isolates of ESKAPE Pathogens.Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.Burden of carbapenem-resistant organisms in the Frankfurt/Main Metropolitan Area in Germany 2012/2013 - first results and experiences after the introduction of legally mandated reporting.Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensRegulation of Clostridium difficile Spore Formation by the SpoIIQ and SpoIIIA Proteins.Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated InfectionsPharmacokinetic/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study.β-Lactam Antibiotics Renaissance.Carbapenems in the USA: focus on doripenem.Nonvolatile salt-free stabilizer for the quantification of polar imipenem and cilastatin in human plasma using hydrophilic interaction chromatography/quadrupole mass spectrometry with contamination sensitive off-axis electrospray.The role of carbapenems in initial therapy for serious Gram-negative infections.Susceptible, intermediate, and resistant - the intensity of antibiotic action.Imipenem Resistant Pseudomonas aeruginosa: The fall of the final quarterback.Phytochemistry and Preliminary Assessment of the Antibacterial Activity of Chloroform Extract of Amburana cearensis (Allemão) A.C. Sm. against Klebsiella pneumoniae Carbapenemase-Producing Strains.Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.A Burkholderia cenocepacia MurJ (MviN) homolog is essential for cell wall peptidoglycan synthesis and bacterial viabilityIn vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center.Escherichia coli Overexpressing a Baeyer-Villiger Monooxygenase from Acinetobacter radioresistens Becomes Resistant to Imipenem.Susceptibilities of common bacterial isolates from oman to old and new antibiotics.Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.Activity of imipenem against Klebsiella pneumoniae biofilms in vitro and in vivo.Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene.Evaluation of different phenotypic tests for detection of metallo-β-lactamases in imipenem-resistant Pseudomonas aeruginosa.Antibiotic sensitivity pattern of Klebsiella species in burn wounds at Bai Jerbai Wadia hospital for children, Mumbai, India-a 21 year study.Public health need versus sales of antibacterial agents active against multidrug-resistant bacteria: a historical perspective.Imipenem-associated encephalopathy: alert to physicians.Comparative analysis of a cryptic thienamycin-like gene cluster identified in Streptomyces flavogriseus by genome mining.Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.Organocatalyzed stereospecific C-C bond formation of β-lactams.Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.
P2860
Q24198268-3099411A-2AD1-4295-BD4E-42A038C6DB01Q24235566-48D6A4B7-A3C8-4F24-99D2-E316407A0A5CQ24634999-AEF341D1-99EE-4093-ACF2-E449019CDC56Q27650232-51FB4660-0412-4F83-A640-7BE17326088FQ28258687-4263A3F9-D28E-42A4-B530-C8CCF9229E54Q28289744-D6E82B36-A730-4EB3-8817-8BC0E442BC22Q28551453-806720C4-FC59-4541-9A62-60D8CFE8FDE3Q28752557-FB07F674-0B30-4613-8B88-B1EF812C2E60Q30249262-F64B8534-9A48-4A7F-9528-617309DA67F8Q33645667-BFA0FB6C-DCEE-477D-B121-FEB6187C9FDFQ34026343-A75C4643-3877-4C32-B170-5582A48DD1B7Q34084965-7736E207-B20B-4D87-8133-A17D417106ECQ34570886-F8D511AB-171E-4715-BB62-0A1233A270FEQ35806531-3B7ECC95-A72C-4A33-9377-7ABC849D4644Q36210431-AFDE6518-00FC-4053-99AF-72BBCA868A57Q36262753-67A809F0-1344-4144-AA8F-DA96798ED484Q36683689-AEC1A51E-FA80-48A1-AF3D-01571100689BQ36960048-84C67DDF-846D-4F8D-975C-CCFB92CF2DF8Q37106300-D7BBB9F2-C279-4D78-B828-0617794CB8ABQ37169849-37D4D117-3AF1-460E-8B5E-E196EDD8CA92Q37239104-6AC2CA06-B701-4199-B6C2-F33C1BA9B055Q38543520-A89D6260-21B4-4D62-BD36-533765FC1BC1Q38628561-D1210C73-2093-4BA9-9E34-E12FC7D60587Q38844899-706D7388-C797-46AD-939A-0E5177FBEB3DQ39000262-5C84A8A7-6A1D-4ED5-A075-2D250D251BC3Q40412701-54730636-49C5-42BA-A5A5-AE91F9E4ABA3Q40439693-15AF5619-85BD-4747-B50B-A7ED09CE19E5Q41272045-C53E7536-9273-490C-ACB8-3A684EA14661Q41516734-2393E722-5AFF-4CFD-89C6-6F9BCCBA3703Q41853056-77B6CAD4-3F88-4FC0-B87E-F1968BC570ABQ41963870-80149D4C-F9FF-44D0-BE66-D05DC9713394Q42232084-AC4E04C1-F4C3-4D77-8E9C-820DCF6DAEABQ42361791-91EC256B-1EC4-4008-983B-CB234883DB01Q42374969-6231C19F-093A-40B5-95FC-BA29EEA458ADQ42408892-53E428D0-B467-4BF2-B534-CDE023DA4BF6Q43118005-372D3D58-12CF-4626-A470-7875448C82B9Q43753805-57E3DF4E-A1BD-439C-BB12-88617D9EB2BEQ45954223-5C5477BD-BFD1-424A-8F42-12FD6827F252Q46403956-7A09310E-D3F6-4192-99CE-29C98097E7A3Q47126542-1961652E-81DC-4FDC-AB57-63F54B18AD4D
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Two decades of imipenem therapy.
@ast
Two decades of imipenem therapy.
@en
type
label
Two decades of imipenem therapy.
@ast
Two decades of imipenem therapy.
@en
prefLabel
Two decades of imipenem therapy.
@ast
Two decades of imipenem therapy.
@en
P2093
P356
P1476
Two decades of imipenem therapy.
@en
P2093
Goldstein EJ
Rodloff AC
P304
P356
10.1093/JAC/DKL354
P407
P577
2006-09-22T00:00:00Z